MA42527A - Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation - Google Patents

Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation

Info

Publication number
MA42527A
MA42527A MA042527A MA42527A MA42527A MA 42527 A MA42527 A MA 42527A MA 042527 A MA042527 A MA 042527A MA 42527 A MA42527 A MA 42527A MA 42527 A MA42527 A MA 42527A
Authority
MA
Morocco
Prior art keywords
compositions
methods
receptor agonists
ht2c receptor
ht2c
Prior art date
Application number
MA042527A
Other languages
English (en)
Inventor
Konrad Feichtinger
Juerg Lehmann
Albert S Ren
Graeme Semple
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MA42527A publication Critical patent/MA42527A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA042527A 2015-07-31 2016-07-28 Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation MA42527A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562199382P 2015-07-31 2015-07-31

Publications (1)

Publication Number Publication Date
MA42527A true MA42527A (fr) 2021-04-07

Family

ID=56684262

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042527A MA42527A (fr) 2015-07-31 2016-07-28 Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation

Country Status (14)

Country Link
US (4) US10272094B2 (fr)
EP (1) EP3328835B1 (fr)
JP (1) JP6789578B2 (fr)
KR (1) KR20180031035A (fr)
CN (1) CN108137508B (fr)
AU (1) AU2016302755B2 (fr)
BR (1) BR112018001707A2 (fr)
CA (1) CA3002525A1 (fr)
EA (1) EA039412B1 (fr)
HK (1) HK1255850A1 (fr)
IL (1) IL257107B (fr)
MA (1) MA42527A (fr)
MX (1) MX375045B (fr)
WO (1) WO2017023679A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3328835B1 (fr) * 2015-07-31 2022-10-12 Arena Pharmaceuticals, Inc. Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
EP3870292A4 (fr) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York Combinaison d'un inhibiteur de réabsorption spécifique de la sérotonine et d'un agoniste partiel du récepteur de la sérotonine 1a pour réduire la dyskinésie induite par l-dopa
CN110668951B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 一种盐酸司来吉兰的合成工艺
CN110642721B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 盐酸司来吉兰的制备方法
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
WO2023279012A2 (fr) * 2021-06-29 2023-01-05 Tusimple, Inc. Systèmes et procédés pour faire fonctionner un véhicule autonome
US12227206B2 (en) 2021-10-14 2025-02-18 Tusimple, Inc. Systems and methods for operating an autonomous vehicle

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180733A (en) * 1990-03-30 1993-01-19 Abbott Laboratories Biogenic amine uptake inhibitors
WO1992018005A1 (fr) 1991-04-16 1992-10-29 National Institutes Of Health Procede de traitement de la trichotillomanie et de l'onychophagie
CA2482195A1 (fr) 2002-04-12 2003-10-23 The University Of Chicago Agonistes de recepteur active frx (farnesoid x receptor)
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
TW200307682A (en) * 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
US7704993B2 (en) * 2003-06-17 2010-04-27 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
BRPI0414186A (pt) * 2003-10-08 2006-10-31 Lilly Co Eli compostos, métodos de antagonizar a atividade de cetp, de tratar ou prevenir uma doença, de diminuir o colesterol ldl plasmático em um mamìmero, de tratar e/ou prevenir seqüelas patológicas, formulação farmacêutica, e, uso de um composto
US20120253036A1 (en) * 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
JP6198715B2 (ja) * 2012-03-06 2017-09-20 武田薬品工業株式会社 三環性化合物
US10118926B2 (en) * 2012-09-14 2018-11-06 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
EP3328835B1 (fr) * 2015-07-31 2022-10-12 Arena Pharmaceuticals, Inc. Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation

Also Published As

Publication number Publication date
JP2018522025A (ja) 2018-08-09
WO2017023679A1 (fr) 2017-02-09
EA039412B1 (ru) 2022-01-25
EA201890402A1 (ru) 2018-09-28
JP6789578B2 (ja) 2020-11-25
BR112018001707A2 (pt) 2018-09-18
US10272094B2 (en) 2019-04-30
US20200383993A1 (en) 2020-12-10
AU2016302755A1 (en) 2018-03-15
IL257107B (en) 2021-03-25
US20200078368A1 (en) 2020-03-12
US20230055376A1 (en) 2023-02-23
US11395824B2 (en) 2022-07-26
MX375045B (es) 2025-03-06
AU2016302755B2 (en) 2020-09-10
MX2018001380A (es) 2018-06-15
CN108137508A (zh) 2018-06-08
EP3328835A1 (fr) 2018-06-06
CN108137508B (zh) 2021-08-27
CA3002525A1 (fr) 2017-02-09
NZ739883A (en) 2021-03-26
KR20180031035A (ko) 2018-03-27
IL257107A (en) 2018-03-29
US10624900B2 (en) 2020-04-21
US20180214455A1 (en) 2018-08-02
HK1255850A1 (zh) 2019-08-30
EP3328835B1 (fr) 2022-10-12

Similar Documents

Publication Publication Date Title
MA42527A (fr) Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation
EP3704239A4 (fr) Compositions de casz et procédés d'utilisation
EP3600318A4 (fr) Procédés d'utilisation d'inhibiteurs d'ehmt2
EP3359523A4 (fr) Compositions d'oligonucléotides et procédés associés
EP3325017A4 (fr) Compositions d'oligonucléotides et procédés associés
EP3352774A4 (fr) Compositions de flavonoïdes et procédés d'utilisation
MA41613A (fr) Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
EP3373906A4 (fr) Compositions et procédés destinés à une application sur la peau
IL255171A0 (en) 5-Hydroxytryptamine 2-C receptor agonists. and preparations and methods of use
EP3380101A4 (fr) Composés inhibiteurs d'eif4-a et procédés associés
MA43380A (fr) Récepteurs chimériques modifiés et compositions et procédés associés
EP3621660A4 (fr) Compositions et procédés d'utilisation de capsides arc
MA40921A (fr) Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
EP3414321A4 (fr) Compositions améliorant vcn et procédés d'utilisation desdites compositions
EP3394065A4 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
EP3303435A4 (fr) Hydrofluoroléfines et procédés d'utilisation associés
EP3386927A4 (fr) Compositions polymères et procédés d'utilisation
EP3688011A4 (fr) Compositions peptidiques et procédés d'utilisation de ces compositions
EP3316894A4 (fr) Composés et compositions comprenant des oligodésoxynucléotides phosphorothioés, et procédés d'utilisation associés
EP3384274A4 (fr) Dispositifs et procédés de caracterisation d'échantillon
EP3478277A4 (fr) Compositions anti-acné et procédés d'utilisation
EP3289064A4 (fr) Compositions et procédés pour la détection d'allergènes
EP3302558A4 (fr) Agents anticancéreux et procédés d'utilisation
IL264682B (en) 5-HT2C receptor agonists and preparations and methods of use
MA52098A (fr) Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation